NCT02902601

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to investigate the safety and tolerability of JNJ 54175446 in participants with Major Depressive Disorder (MDD).

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	JNJ-54175446, 600 mg	Participants will receive JNJ-54175446, 600 mg as an oral suspension.
DRUG	JNJ-54175446, 150 mg	Participants will receive JNJ-54175446, 150 mg as an oral suspension.
OTHER	Placebo	Matching placebo to JNJ-54175446

Timeline

• Start date: 2016-10-17
• Primary completion: 2017-06-02
• Completion: 2017-06-07
• First posted: 2016-09-16
• Last updated: 2025-04-27

Locations

4 sites across 2 countries: Germany, Netherlands